View in EDS HTML Full Text PDF Full Text

A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.

Saved in:
Bibliographic Details
Title: A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.
Authors: Ren, Hong1 (AUTHOR), Zhang, Wei2,3 (AUTHOR), Ouyang, Yan1 (AUTHOR), Guo, Junhong3 (AUTHOR), Xu, Hong4 (AUTHOR), Ma, Jie5 (AUTHOR), Luo, Xiaoping6 (AUTHOR), Pan, Xiaoxia1 (AUTHOR), Yuan, Yun2 (AUTHOR), Shen, Qian4 (AUTHOR), Li, Bin7 (AUTHOR), Feng, Qiqi7 (AUTHOR), Liu, Shi7 (AUTHOR), Chen, Nan1 (AUTHOR) cnrj100@126.com
Source: Orphanet Journal of Rare Diseases. 8/4/2025, Vol. 20 Issue 1, p1-12. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17501172
DOI:10.1186/s13023-025-03950-7